The Centre for Cellular and Molecular Platforms (C-CAMP) on Tuesday announced the expansion and augmentation of its collaboration with Agilent Technologies, which specialises in cutting-edge bio-analytics and biotechnology platforms.

C-CAMP said that the second phase of this partnership will broaden shared access to advanced analytical and mass spectrometry-based capabilities that will support life sciences and therapeutics research in India.

The expanded collaboration focuses on making high‑resolution analytical platforms available through C‑CAMP’s shared infrastructure, supporting applications such as biotherapeutic characterisation, oligonucleotide research, and quantitative biomolecular analysis.

It added that the model is designed to enable researchers from startups, academia, and industry to access advanced analytical workflows and deep scientific know-how without needing a direct capital investment in specialised instrumentation or facilities.

Through this collaboration, Agilent and C‑CAMP aim to help reduce entry barriers and support reliable, reproducible science across the research and development continuum.

One of the major milestones from phase I of this collaboration includes the LC/MS-based characterisation of Liraglutide, a GLP-1 agonist used in diabetes and obesity management, using Agilent’s Mass Spectrometry platform.

“This research is a game-changer for therapeutic peptide development, ensuring compliance with FDA safety standards and enhancing drug efficacy,” C‑CAMP said.

Taslimarif Saiyed, director and CEO, C‑CAMP, said, “In the coming years, we believe such collaborations will play a key role in enabling technology development and accelerating science-led innovation.”

“Joint efforts will kick off with a focused training programme designed to equip scientists from startups and industry with the skills to assess critical quality attributes (CQAs) in biopharmaceutical development using high- resolution LC-MS/MS,” C‑CAMP said.